Features Screener Stocks Charts
Sign In Sign Up

Glaxosmithkline Pharmaceuticals Ltd. Cash Flow Statement

NSE:GLAXO | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

1.03x

GLAXO's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.

Free Cash Flow

₹12.67B

GLAXO's free cash flow was ₹12.67B in FY 2025, up 130.0% from FY 2024.

Dividend Coverage

1.7x

GLAXO's free cash flow covered dividends 1.7x in FY 2025 but leaves limited surplus.

CapEx Intensity

1.8%

Capital expenditure was 1.8% of operating cash flow in FY 2025 for GLAXO, indicating a capital-light business.

2-year GLAXO cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 9.60B 12.55B
Cash flow Operating Activities 5.82B 12.90B
Investments in PPE -312.22M -230.22M
Cash flow Investing Activities 87.12M -458.01M
Dividend Paid -5.42B -7.49B
Cash flow Financing Activities -5.61B -7.69B
Cash at beginning of period 349.41M 641.71M
Cash at end of period 641.71M 5.39B
Free Cash Flow 5.51B 12.67B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025